The influence of structural and functional albumin properties on the life quality in patients with decompensated liver cirrhosis
https://doi.org/10.21518/ms2023-130
Abstract
Introduction. The gradual progression of liver cirrhosis with the development of complications has a negative impact on the life quality of patients with this disease. Modern therapeutic strategies are aimed not only at disease compensating, but much attention is paid to improving the quality of life. No data exists on the effect of serum albumin levels, their structural and functional activity, on the quality of life of patients with cirrhosis.
Aim. To evaluate the relationship between serum albumin concentration, its structural configuration (DR), functional properties (BE, RTQ, DTE) and life quality in patients with decompensated liver cirrhosis.
Materials and methods. The severity of the structural and functional properties of albumin was evaluated in decompensated patients (n = 50) using electron paramagnetic resonance spectroscopy (EPR spectroscopy). Patients’ quality of life was examined using a standardised SF-36 questionnaire.
Results. Pathological changes in DR were observed in 100% of patients, a decrease in BE – in 90%, a violation of RTQ – in 82% of cases, a decrease in DTE was recorded in 76% of patients. The correlation between the level of serum albumin and indicators of physical functioning (PF), role functioning due to emotional state (RE) was ρ = 0,294. Structural and functional albumin properties were related to low indicators of the physical component of health (p < 0,05).
Conclusions. А decline in serum albumin levels, a violation of its conformation and functional properties has a negative impact on the quality of life of patients with decompensated liver cirrhosis.
About the Authors
A. A. Turkina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Anastasia A. Turkina, Postgraduate Student, Department of Propaedeutics of Internal Diseases Gastroenterology and Hepatology
1, Bldg. 1, Pogodinskaya St., Moscow, 119991
M. V. Maevskaya
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Marina V. Maevskaya, Dr. Sci. (Med.), Professor
1, Bldg. 1, Pogodinskaya St., Moscow, 119991
M. S. Zharkova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Maria S. Zharkova, Cand. Sci. (Med.), Head of the Hepatology Department, Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology
1, Bldg. 1, Pogodinskaya St., Moscow, 119991
V. T. Ivashkin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Vladimir T. Ivashkin, Acad. RAS, Dr. Sci. (Med.), Professor, Head of the Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology
1, Bldg. 1, Pogodinskaya St., Moscow, 119991
References
1. Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Zhigalova S.B., Kitsenko E.A., Manukyan G.V. et al. Clinical Recommendations of the Russian Scientific Liver Society and Russian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;(6):56–102. (In Russ.) Available at: https://www.gastro-j.ru/jour/article/view/621.
2. Younossi Z.M., Boparai N., McCormick M., Price L.L., Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol. 2001;96(2):579–583. https://doi.org/10.1111/j.1572-0241.2001.03537.x.
3. Marchesini G., Bianchi G., Amodio P., Salerno F., Merli M., Panella C. et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology. 2001;120(1):170–178. https://doi.org/10.1053/gast.2001.21193.
4. Younossi Z.M., Boparai N., Price L.L., Kiwi M.L., McCormick M., Guyatt G. Healthrelated quality of life of patients in chronic liver disease: the impact of type and severity of liver disease. Am J Gastroenterol. 2001;96(7):2199–2205. https://doi.org/10.1111/j.1572-0241.2001.03956.x.
5. Lins L., Carvalho F.M. SF-36 total score as a single measure of health- related quality of life: Scoping review. SAGE Open Medicine. 2016;4:2050312116671725. https://doi.org/10.1177/2050312116671725.
6. Janani K., Jain M., Vargese J., Srinivasan V., Harika K., Michael T., Venkataraman J. Health-related quality of life in liver cirrhosis patients using SF-36 and CLDQ questionnaires. Clin Exp Hepatol. 2018;4(4):232–239. https://doi.org/10.5114/ceh.2018.80124.
7. Domenicali M., Baldassarre M., Giannone F.A., Naldi M., Mastroroberto M., Biselli M. et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology. 2014;60(6):1851–1860. https://doi.org/10.1002/hep.27322.
8. Baldassarre M., Naldi M., Zaccherini G., Bartoletti M., Antognoli A, Laggetta M. et al. Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology. 2021;74(4):2058–2073. https://doi.org/10.1002/hep.31798.
9. McPhail S.M., Amarasena S., Stuart K.A., Hayward K., Gupta R., Brain D. et al. Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis. JGH Open. 2020;5(1):133–142. https://doi.org/10.1002/jgh3.12462.
10. Les I., Doval E., Flavia M., Jacas C., Cárdenas G., Esteban R. et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol. 2010;22(2):221–227. https://doi.org/10.1097/MEG.0b013e3283319975.
11. Uzbekov M.G., Syrejshchikova T.I., Maximova N.M., Smolina N.V., Dobretsov G.E., Brilliantova V.V., Shikhov S.N. Conformational changes of blood serum albumin molecule in patients with anxious depression. Sotsialnaya i Klinicheskaya Psikhiatriya. 2020;(3):13–16. (In Russ.) Available at: https://psychiatr.ru/magazine/scp/121/1843.
12. Sokolova S.V., Sozarukova M.M., Khannanova A.N., Grishina N.K., Portnova G.V., Proskurnina E.V. Antioxidant status in patients with paranoid schizophrenia and Alzheimer disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(6):82–87. (In Russ.) https://doi.org/10.17116/jnevro202012006182.
13. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuroрsychopharmacol Biol Psychiatry. 1995;19(1):1138. https://doi.org/10.1016/0278-5846(94)00101-m.
14. Liu T., Zhong S., Liao X., Chen J., He T., Lai S., Jia Y. A meta-analysis of oxidative stress markers in depression. PLoS ONE. 2015;10(10):e0138904. https://doi.org/10.1371/journal.pone.0138904.
15. Engelmann C., Clària J., Szabo G., Bosch J., Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol. 2021;75(1):49–66. https://doi.org/10.1016/j.jhep.2021.01.002.
16. Baldassarre M., Domenicali M., Naldi M., Laggetta M., Giannone F.A., Biselli M. et al. Albumin Homodimers in Patients with Cirrhosis: Clinical and Prognostic Relevance of a Novel Identified Structural Alteration of the Molecule. Sci Rep. 2016;6:35987. https://doi.org/10.1038/srep35987.
17. Pomacu M.M., Trașcă M.D., Pădureanu V., Bugă A.M., Andrei A.M., Stănciulescu E.C. et al. Interrelation of inflammation and oxidative stress in liver cirrhosis. Exp Тther Мed. 2021;21(6):602. https://doi.org/10.3892/etm.2021.10034.
18. Mooli R.G.R., Mukhi D., Ramakrishnan S.K. Oxidative Stress and Redox Signaling in the Pathophysiology of Liver Diseases. Compr Physiol. 2022;12(2):3167–3192. https://doi.org/10.1002/cphy.c200021.
19. Bernardi M., Angeli P., Claria J., Moreau R., Gines P., Jalan R. et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut. 2020;69(6):1127–1138. https://doi.org/10.1136/gutjnl-2019-318843.
20. de Mattos Â.Z., Simonetto D.A., Terra C., Farias A.Q., Bittencourt P.L., Pase T.H.S. et al. Alliance of Brazilian Centers for Cirrhosis Care – the ABC Group. Albumin administration in patients with cirrhosis: Current role and novel perspectives. World J Gastroenterol. 2022;28(33):4773–4786. https://doi.org/10.3748/wjg.v28.i33.4773.
21. Gustot T., Jalan R. Acute-on-chronic liver failure in patients with alcoholrelated liver disease. J Hepatol. 2019;70(2):319–327. https://doi.org/10.1016/j.jhep.2018.12.008.
22. Jalan R., Stadlbauer V., Sen S., Cheshire L., Chang Y.M., Mookerjee R.P. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study. Crit Care. 2012;16(6):R227. https://doi.org/10.1186/cc11882.
23. Michelena J., Altamirano J., Abraldes J.G., Affò S., Morales-Ibanez O., Sancho-Bru P. et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. Hepatology. 2015;62(3):762–772. https://doi.org/10.1002/hep.27779.
Review
For citations:
Turkina AA, Maevskaya MV, Zharkova MS, Ivashkin VT. The influence of structural and functional albumin properties on the life quality in patients with decompensated liver cirrhosis. Meditsinskiy sovet = Medical Council. 2023;(8):113-118. (In Russ.) https://doi.org/10.21518/ms2023-130
Views:
463
Email this article 